Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05588843 · ClinicalTrials.gov registry record · Phase 2
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
A Phase 2 study of Colitis, Ulcerative, sponsored by Sanofi.
- Active
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT05588843 is a Phase 2 study of Colitis, Ulcerative that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 187 participants, below the 399-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05588843, a Phase 2 study of Colitis, Ulcerative, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to severe UC. All participants will receive a total of 52 weeks (a 12-week induction treatment phase and a 40-week maintenance phase) of study treatment, except if treatment should be discontinued per investigator's assessment. At the end of the first 12 weeks of induction treatment, all participants in clinical response or remission will be offered study treatment up to 40 weeks and will continue with the same blinded treatment that was assigned. Participants who do not achieve clinical response or remission at the end of the initial 12 weeks induction treatment will roll over in an open-label treatment arm and will be treated with SAR443122 at the highest tested dose. In addition, participants from the maintenance treatment that lose clinical efficacy at any time up to V10/Week 40 (Week 28 of maintenance) will be offered to roll over in the open-label treatment arm with SAR443122 at the highest dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SAR443122
Study Locations (20)
Texas
- Houston Methodist Hospital- Site Number : 8400023 - Houston
- 1960 Family Practice- Site Number : 8400019 - Houston
- GI Alliance - Mansfield- Site Number : 8400010 - Mansfield
- Integrity Research - Sugar Land- Site Number : 8400026 - Sugar Land
Other
- Investigational Site Number : 0320002 - Buenos Aires
- Investigational Site Number : 0320004 - Córdoba
- Investigational Site Number : 0320005 - Córdoba
New York
- NY Scientific- Site Number : 8400013 - Brooklyn
- Pioneer Clinical Research - New York- Site Number : 8400017 - New York
California
- Om Research - Lancaster - 15th Street West- Site Number : 8400014 - Lancaster
Georgia
- Agile Clinical Research Trials- Site Number : 8400024 - Atlanta
Illinois
- Endeavor Health - Evanston Hospital- Site Number : 8400027 - Evanston
Missouri
- BVL Research- Site Number : 8400015 - Liberty
Nevada
- Vector Clinical Trials- Site Number : 8400004 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2022-11-25 |
| Est. Completion | 2026-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05588843
The ClinicalTrials.gov registry entry for NCT05588843 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 399-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (53% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colitis, Ulcerative appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05588843 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, Other, New York.
Frequently Asked Questions
What is clinical trial NCT05588843 about?
NCT05588843 is a clinical study titled "Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis". This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple ...
What is the current status of trial NCT05588843?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2022-11-25. Estimated completion is 2026-12-02.
What conditions does trial NCT05588843 study?
This clinical trial studies the following conditions: Colitis, Ulcerative.
What interventions are being tested in trial NCT05588843?
The interventions under investigation include: Placebo (DRUG), SAR443122 (DRUG).
Who is sponsoring clinical trial NCT05588843?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05588843 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colitis, Ulcerative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RECRUITING · Phase 2
-
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
RECRUITING · Phase 2
-
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.